亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

深圳市思科達生物技術(shù)有限公司  

專業(yè)經(jīng)營化學(xué)標(biāo)準(zhǔn)品，對照品
搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人：楊森
  • 電話：0755-89218244
  • 郵件：lq@szskerd.com
  • 傳真：0755-28984072
  • QQ：793285927
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
福沙吡坦
單價 面議對比
詢價 暫無
發(fā)貨 廣東深圳市付款后3天內(nèi)
品牌 深圳市思科達生物技術(shù)有限公司
過期 長期有效
更新 2014-12-02 13:09
 
詳細信息
 產(chǎn)品名稱：福沙吡坦 雜質(zhì) 標(biāo)準(zhǔn)品 對照品 265121-04-8

產(chǎn)品關(guān)鍵詞：福沙吡坦 雜質(zhì) 標(biāo)準(zhǔn)品 對照品 265121-04-8

福沙吡坦二甲葡胺                                Fosaprepitant                              100mg

SSR-福沙匹坦                                       SSR-Fosaprepitant                      10mg/25mg/50mg

RRR-福沙匹坦                                      RRR-Fosaprepitant                     10mg/25mg/50mg

SSS-福沙匹坦                                        SSS-Fosaprepitant                      10mg/25mg/50mg

RSR-福沙匹坦                                       RSR-Fosaprepitant                     10mg/25mg/50mg

SRS-福沙匹坦                                       SRS-Fosaprepitant                      10mg/25mg/50mg

SRR-福沙匹坦                                       SRR-Fosaprepitant                     10mg/25mg/50mg

RSS-福沙匹坦                                       RSS-Fosaprepitant                      10mg/25mg/50mg
©2025 深圳市思科達生物技術(shù)有限公司 版權(quán)所有   技術(shù)支持：化工網(wǎng)   訪問量:13002  
 
主站蜘蛛池模板： | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |